Karina Anne Keogh, MD | |
200 1st St Sw, Rochester, MN 55905-0001 | |
(507) 284-2511 | |
Not Available |
Full Name | Karina Anne Keogh |
---|---|
Gender | Female |
Speciality | Pulmonary Disease |
Experience | 27 Years |
Location | 200 1st St Sw, Rochester, Minnesota |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1356315121 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RP1001X | Internal Medicine - Pulmonary Disease | 42931 (Minnesota) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Mayo Clinic Hospital Rochester | Rochester, MN | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Mayo Clinic | 6507778255 | 4232 |
Mayo Clinic Health System-southeast Minnesota Region | 4385556703 | 573 |
News Archive
GlaxoSmithKline PLC said it will pay the U.S. government $3 billion to settle several long-running criminal and civil investigations into the company, including allegations that Glaxo marketed some drugs illegally and defrauded the Medicaid program. The settlement will also cover a Department of Justice probe into Glaxo's development and marketing of the diabetes drug Avandia, which has been linked to heart attack risks.
Developing brains in newborns have a sizable pool of a certain type of immature progenitor cell that can be expanded and induced to replace cells lost to brain injury.
Health and Human Services Secretary Kathleen Sebelius has enlisted the talent and resources of some of the nation's leading universities, community colleges, and major research centers to advance the widespread adoption and meaningful use of health information technology (health IT).
Halozyme Therapeutics, Inc. announced today that the European Commission has approved Roche's new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.
› Verified 1 days ago
Entity Name | Mayo Clinic |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1922074434 PECOS PAC ID: 6507778255 Enrollment ID: O20031103000285 |
News Archive
GlaxoSmithKline PLC said it will pay the U.S. government $3 billion to settle several long-running criminal and civil investigations into the company, including allegations that Glaxo marketed some drugs illegally and defrauded the Medicaid program. The settlement will also cover a Department of Justice probe into Glaxo's development and marketing of the diabetes drug Avandia, which has been linked to heart attack risks.
Developing brains in newborns have a sizable pool of a certain type of immature progenitor cell that can be expanded and induced to replace cells lost to brain injury.
Health and Human Services Secretary Kathleen Sebelius has enlisted the talent and resources of some of the nation's leading universities, community colleges, and major research centers to advance the widespread adoption and meaningful use of health information technology (health IT).
Halozyme Therapeutics, Inc. announced today that the European Commission has approved Roche's new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.
› Verified 1 days ago
Entity Name | Mayo Clinic Health System-lake City |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1164463659 PECOS PAC ID: 1951213487 Enrollment ID: O20031104000095 |
News Archive
GlaxoSmithKline PLC said it will pay the U.S. government $3 billion to settle several long-running criminal and civil investigations into the company, including allegations that Glaxo marketed some drugs illegally and defrauded the Medicaid program. The settlement will also cover a Department of Justice probe into Glaxo's development and marketing of the diabetes drug Avandia, which has been linked to heart attack risks.
Developing brains in newborns have a sizable pool of a certain type of immature progenitor cell that can be expanded and induced to replace cells lost to brain injury.
Health and Human Services Secretary Kathleen Sebelius has enlisted the talent and resources of some of the nation's leading universities, community colleges, and major research centers to advance the widespread adoption and meaningful use of health information technology (health IT).
Halozyme Therapeutics, Inc. announced today that the European Commission has approved Roche's new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.
› Verified 1 days ago
Entity Name | Mayo Clinic Health System-southeast Minnesota Region |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1891701637 PECOS PAC ID: 4385556703 Enrollment ID: O20031104000408 |
News Archive
GlaxoSmithKline PLC said it will pay the U.S. government $3 billion to settle several long-running criminal and civil investigations into the company, including allegations that Glaxo marketed some drugs illegally and defrauded the Medicaid program. The settlement will also cover a Department of Justice probe into Glaxo's development and marketing of the diabetes drug Avandia, which has been linked to heart attack risks.
Developing brains in newborns have a sizable pool of a certain type of immature progenitor cell that can be expanded and induced to replace cells lost to brain injury.
Health and Human Services Secretary Kathleen Sebelius has enlisted the talent and resources of some of the nation's leading universities, community colleges, and major research centers to advance the widespread adoption and meaningful use of health information technology (health IT).
Halozyme Therapeutics, Inc. announced today that the European Commission has approved Roche's new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.
› Verified 1 days ago
Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1578545422 PECOS PAC ID: 4688585771 Enrollment ID: O20031110000134 |
News Archive
GlaxoSmithKline PLC said it will pay the U.S. government $3 billion to settle several long-running criminal and civil investigations into the company, including allegations that Glaxo marketed some drugs illegally and defrauded the Medicaid program. The settlement will also cover a Department of Justice probe into Glaxo's development and marketing of the diabetes drug Avandia, which has been linked to heart attack risks.
Developing brains in newborns have a sizable pool of a certain type of immature progenitor cell that can be expanded and induced to replace cells lost to brain injury.
Health and Human Services Secretary Kathleen Sebelius has enlisted the talent and resources of some of the nation's leading universities, community colleges, and major research centers to advance the widespread adoption and meaningful use of health information technology (health IT).
Halozyme Therapeutics, Inc. announced today that the European Commission has approved Roche's new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.
› Verified 1 days ago
Entity Name | Mayo Clinic Health System-lake City |
---|---|
Entity Type | Part A Provider - Critical Access Hospital |
Entity Identifiers | NPI Number: 1538113022 PECOS PAC ID: 1951213487 Enrollment ID: O20070711000490 |
News Archive
GlaxoSmithKline PLC said it will pay the U.S. government $3 billion to settle several long-running criminal and civil investigations into the company, including allegations that Glaxo marketed some drugs illegally and defrauded the Medicaid program. The settlement will also cover a Department of Justice probe into Glaxo's development and marketing of the diabetes drug Avandia, which has been linked to heart attack risks.
Developing brains in newborns have a sizable pool of a certain type of immature progenitor cell that can be expanded and induced to replace cells lost to brain injury.
Health and Human Services Secretary Kathleen Sebelius has enlisted the talent and resources of some of the nation's leading universities, community colleges, and major research centers to advance the widespread adoption and meaningful use of health information technology (health IT).
Halozyme Therapeutics, Inc. announced today that the European Commission has approved Roche's new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.
› Verified 1 days ago
Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
---|---|
Entity Type | Part A Provider - Critical Access Hospital |
Entity Identifiers | NPI Number: 1124035282 PECOS PAC ID: 4688585771 Enrollment ID: O20171011003939 |
News Archive
GlaxoSmithKline PLC said it will pay the U.S. government $3 billion to settle several long-running criminal and civil investigations into the company, including allegations that Glaxo marketed some drugs illegally and defrauded the Medicaid program. The settlement will also cover a Department of Justice probe into Glaxo's development and marketing of the diabetes drug Avandia, which has been linked to heart attack risks.
Developing brains in newborns have a sizable pool of a certain type of immature progenitor cell that can be expanded and induced to replace cells lost to brain injury.
Health and Human Services Secretary Kathleen Sebelius has enlisted the talent and resources of some of the nation's leading universities, community colleges, and major research centers to advance the widespread adoption and meaningful use of health information technology (health IT).
Halozyme Therapeutics, Inc. announced today that the European Commission has approved Roche's new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.
› Verified 1 days ago
Entity Name | Mayo Clinic Health System-southeast Minnesota Region |
---|---|
Entity Type | Part A Provider - Critical Access Hospital |
Entity Identifiers | NPI Number: 1063435410 PECOS PAC ID: 4385556703 Enrollment ID: O20171011003946 |
News Archive
GlaxoSmithKline PLC said it will pay the U.S. government $3 billion to settle several long-running criminal and civil investigations into the company, including allegations that Glaxo marketed some drugs illegally and defrauded the Medicaid program. The settlement will also cover a Department of Justice probe into Glaxo's development and marketing of the diabetes drug Avandia, which has been linked to heart attack risks.
Developing brains in newborns have a sizable pool of a certain type of immature progenitor cell that can be expanded and induced to replace cells lost to brain injury.
Health and Human Services Secretary Kathleen Sebelius has enlisted the talent and resources of some of the nation's leading universities, community colleges, and major research centers to advance the widespread adoption and meaningful use of health information technology (health IT).
Halozyme Therapeutics, Inc. announced today that the European Commission has approved Roche's new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Karina Anne Keogh, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Karina Anne Keogh, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 |
News Archive
GlaxoSmithKline PLC said it will pay the U.S. government $3 billion to settle several long-running criminal and civil investigations into the company, including allegations that Glaxo marketed some drugs illegally and defrauded the Medicaid program. The settlement will also cover a Department of Justice probe into Glaxo's development and marketing of the diabetes drug Avandia, which has been linked to heart attack risks.
Developing brains in newborns have a sizable pool of a certain type of immature progenitor cell that can be expanded and induced to replace cells lost to brain injury.
Health and Human Services Secretary Kathleen Sebelius has enlisted the talent and resources of some of the nation's leading universities, community colleges, and major research centers to advance the widespread adoption and meaningful use of health information technology (health IT).
Halozyme Therapeutics, Inc. announced today that the European Commission has approved Roche's new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.
› Verified 1 days ago
Emily Leasure, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Jorge A Velosa, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Michael Ruediger Mueller, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Mr. Karun Singh Badwal, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Michal Reid, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Katherine Desprez Wick, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Dr. Allison Bock, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |